Rethinking endpoints, subgroup analyses, and time-varying treatment in AST-120 CKD research
Journal of the Formosan Medical Association · 2026-08
DOI: 10.1016/j.jfma.2026.08.025 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the Formosan Medical Association, 2026-08. Verfasst von Menglong Li. Beteiligte Einrichtung: Evidence-based Medicine Center, Beijing Luhe Hospital, Capital Medical University, No. 82, Xinhua South Road, Tongzhou District, Beijing, 101149, Chi…. Die Arbeit nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Evidence-based Medicine Center, Beijing Luhe Hospital, Capital Medical University, No. 82, Xinhua South Road, Tongzhou District, Beijing, 101149, China. Electronic address: limenglong_ph@163.com.
Zitieren
APA
Li, M. (2026). Rethinking endpoints, subgroup analyses, and time-varying treatment in AST-120 CKD research. Journal of the Formosan Medical Association. https://doi.org/10.1016/j.jfma.2026.08.025
Vancouver
Li M. Rethinking endpoints, subgroup analyses, and time-varying treatment in AST-120 CKD research. Journal of the Formosan Medical Association. 2026. doi:10.1016/j.jfma.2026.08.025
BibTeX
@article{Li2026,
author = {Li, Menglong},
title = {Rethinking endpoints, subgroup analyses, and time-varying treatment in AST-120 CKD research},
journal = {Journal of the Formosan Medical Association},
year = {2026},
doi = {10.1016/j.jfma.2026.08.025}
}
EUVIMED